Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
Frederick Arce Vargas, Andrew J.S. Furness, Kevin Litchfield et al. · Cancer Cell · 2018
With the use of a mouse model expressing human Fc-gamma receptors (FcγRs), we demonstrated that antibodies with isotypes equivalent to ipilimumab and tremelimumab mediate intra-tumoral regulatory T (Treg) cell depletion in vivo , increasing the CD8 + to Treg cell ratio and promoting tumor rejection. Antibodies with improved FcγR binding profiles drove superior anti-tumor responses and survival. In patients with advanced melanoma, response to ipilimumab was associated with the CD16a-V158F high affinity polymorphism. Such activity only appeared relevant in the context of inflamed tumors, explaining the modest response rates observed in the clinical setting. Our data suggest that the activity of anti-CTLA-4 in inflamed tumors may be improved through enhancement of FcγR binding, whereas poorly infiltrated tumors will likely require combination approaches.
Cited by 588 works. doi:10.1016/j.ccell.2018.02.010 Open-access PDF
Authors
- Frederick Arce Vargas
- Andrew J.S. Furness
- Kevin Litchfield
- Kroopa Joshi
- Rachel Rosenthal
- Ehsan Ghorani
- Isabelle Solomon
- Marta H. Lesko
- Nora Ruef
- Claire Roddie
- Jake Y. Henry
- Lavinia Anne Spain
- Assma Ben Aïssa
- Andrew Georgiou
- Yien Ning Sophia Wong
- Myles J. F. Smith
- D. Strauß
- Andrew J Hayes
- David Nicol
- Tim O'Brien
References
- PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Signatures of mutational processes in human cancer
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Enhancement of Antitumor Immunity by CTLA-4 Blockade
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma